% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • zorrelak69 zorrelak69 Mar 19, 2010 11:07 PM Flag

    CLDX Valuation

    They are not paying for any development costs related to CDX-110. The market value of this company makes no sense.

    Assuming they receive FDA approval of their brain cancer vaccine, they will receive $390 million in milestone payments as well as double digit royalties. Yet the market capitalization is only $170 million. Could anyone explain why investors are discounting the stock so much?

    It is apparent that it works in all trials. Some patients even survived as long as 6 years!

    Does anyone know the break-up of when we receive milestone payments? Is the full $390 upon FDA approval, or are some related to Phase II, Phase III completion?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
3.36-0.01(-0.30%)Oct 24 4:00 PMEDT